191 related articles for article (PubMed ID: 20399911)
21. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction.
Amet N; Gacad M; Petrosyan A; Pao A; Jordan SC; Toyoda M
Transpl Immunol; 2010 Aug; 23(4):170-3. PubMed ID: 20609387
[TBL] [Abstract][Full Text] [Related]
22. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
23. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
24. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
25. Low dose of deoxyguanosine increases IL-2 receptors of IL-2-dependent cultured T cells.
Noma T; Klein B; Yata J; Serrou B
Immunology; 1984 Jun; 52(2):247-52. PubMed ID: 6610631
[TBL] [Abstract][Full Text] [Related]
26. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
27. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor.
Wada Y; Yagihashi A; Terasawa K; Miyao N; Hirata K; Cicciarelli J; Iwaki Y
Artif Organs; 1996 Aug; 20(8):849-52. PubMed ID: 8853794
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis.
Morris PE; Omura GA
Curr Pharm Des; 2000 Jun; 6(9):943-59. PubMed ID: 10828318
[TBL] [Abstract][Full Text] [Related]
29. The effect of deoxyguanosine on human lymphocyte function. I. Analysis of the interference with lymphocyte proliferation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Wadman SK; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2311-7. PubMed ID: 6425399
[TBL] [Abstract][Full Text] [Related]
30. Purine nucleoside phosphorylase deficiency.
Markert ML
Immunodefic Rev; 1991; 3(1):45-81. PubMed ID: 1931007
[TBL] [Abstract][Full Text] [Related]
31. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
32. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
33. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression.
Nelson DM; Butters KA; Markert ML; Reinsmoen NL; McIvor RS
J Immunol; 1995 Mar; 154(6):3006-14. PubMed ID: 7876563
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
[TBL] [Abstract][Full Text] [Related]
35. The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
Deves C; de Assunção TM; Ducati RG; Campos MM; Basso LA; Santos DS; Batista EL
Bone; 2013 Jan; 52(1):167-75. PubMed ID: 23026564
[TBL] [Abstract][Full Text] [Related]
36. B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Clin Exp Immunol; 1984 Apr; 56(1):39-48. PubMed ID: 6424986
[TBL] [Abstract][Full Text] [Related]
37. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
[TBL] [Abstract][Full Text] [Related]
38. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo.
Boldt A; Barten MJ; Sagner A; Mohr FW; Adams V; Dhein S; Gummert JF
Transplantation; 2006 Aug; 82(3):422-7. PubMed ID: 16906043
[TBL] [Abstract][Full Text] [Related]
39. In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor.
Iwata H; Wada Y; Walsh M; Montgomery JA; Hirose H; Mendez R; Cicciarelli J; Iwaki Y
Transplant Proc; 1998 Jun; 30(4):983-6. PubMed ID: 9636397
[No Abstract] [Full Text] [Related]
40. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR).
Wilburn DJ; Dong MK; Gilbertsen RB
Agents Actions; 1993; 39 Spec No():C96-8. PubMed ID: 8273599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
